First patients to receive experimental drug for aggressive leukemia
NCT ID NCT07384715
Summary
This is the first-ever study in people for a new drug called GEN3018. It aims to find a safe and effective dose for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or is resistant to standard treatments. The main goals are to check the drug's safety and see if it shows early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus Universitetshospital - Skejby
RECRUITINGAarhus, 8200, Denmark
-
Copenhagen Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.